Tibor Kovacsovics, MD
Tibor Kovacsovics is the Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies, as well as Associate Director of Hematological Malignancy Clinical Research in the HCI Clinical Trials Office, at University of Utah Health Care. He graduated from the University of Geneva Medical School, and was a Resident in Internal Medicine at the Clinique Médicale Thérapeutique at Geneva University Hospital, Switzerland, after which he became Chief Resident at the same institution.
Dr. Kovacsovics completed training as a Research Assistant at the Institute of Biochemistry at the University of Lausanne, Switzerland. He then became a Clinical and Research Fellow in Medicine, Hematology-Oncology, at Massachusetts General Hospital and Brigham and Women’s Hospital, Harvard Medical School.
Dr. Kovacsovics brings to the University of Utah extensive expertise in the clinical management of patients with hematologic malignancies, particularly acute leukemias. He has research interests in acute myeloid leukemia (aml), acute lymphoblastic leukemia, chemotherapy, and hematopoietic stem cell transplantation.
Representative Publications:
Functional Integration of Acute Myeloid Leukemia Into the Vascular Niche
Induction Bortezomib in Al Amyloidosis Followed by High Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Retrospective Study
Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening
Outpatient Consolidation Treatment With Clofarabine in a Phase 2 Study of Older Adult Patients With Previously Untreated Acute Myelogenous Leukemia
Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial
